The Strait of Hormuz is almost silent, with zero ships entering in 24 hours, and oil tankers are playing the stealth game.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SK hynix (SKHY.US) subsidiary Flash Division reportedly selects Goldman Sachs and Morgan Stanley to lead, aiming for a US IPO in 2027
According to sources familiar with the matter, Solidigm, the flash memory subsidiary of SK hynix (SKHY.US), has selected the lead banks for its planned US IPO next year, with Goldman Sachs and Morgan Stanley responsible for the offering.
KS Industry holds extraordinary shareholder meeting, elects directors
KS Industry held an extraordinary shareholder meeting on Oct. 8, 2026. Shareholders passed resolutions to appoint Kim In-gyeom as an internal director. Approval was also secured to appoint Chen Yang as an internal director. Resolutions to appoint Kim Woo-joon, Cha Haeng-jeon as independent directors were adopted. The votes authorized these board appointments; the filing did not confirm the appointments have been implemented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KS Industry Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900252), on October 08, 2026, and is solely responsible for the information contained therein.
Pfizer (PFE.US) Tukysa approved in the United States for first-line breast cancer treatment
Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor, Tukysa (tucatinib), as part of a combination regimen for first-line maintenance treatment of a certain type of breast cancer.
Veteran Danny Deep from General Dynamics appointed as the next CEO
